FDLI Conference In Brief
This article was originally published in The Tan Sheet
Executive Summary
Law professor dubs Zicam AER case one to watch in 2012; Cargill draws legal line between customers’ food and supplement products.
You may also be interested in...
In Brief
CHPA stands up for gluten in OTCs; Sen. Durbin targets energy drink supplement labeling; CDC report delves into U.S. nutritional data; P&G files tooth whitening patent suit against Be Well Health Marketing; more news In Brief.
Matrixx Decision Raises More Disclosure Questions – Law Professor
The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.